Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the studydrug, OTP-01, is for patients with solid tumors through understanding how it is toleratedand any side effects that it may cause. The trial will also see if OTP-01 causes tumorsto shrink and how the body processes OTP-01 by measuring drug levels in the blood.